Scentech Medical News
16 articles
מנכ"ל רשת 13 לשעבר מבקש "לנער" את הדירקטוריון של נקסט ג'ן
The merger between the publicly traded company Next Gen and Scent-Tech Medical, a company that developed a device for diagnosing infectious diseases by breath, has been delayed for over two years. The delay is due to the Israel Securities Authority refusing to approve the merger. Additionally, a potential power struggle between two investor groups, each holding over 5% of the companys shares, is emerging. The investor groups are led by Avi Ben Tal, former CEO of Channel 13, and Moshe Berman. They have requested to halt the tenure of Next Gens board of directors and appoint their own candidates.
Acquired-byManagement Changes
הדו"ח שנקסט גן לא חשבה שיעניין את המשקיעים: "סנט־טק לא בשלה להשקעה, צריכה לשנות פאזה" כלכליסט
כדי להציל את המיזוג: סנט-טק מזיזה את הרשטיק, ומביאה את מנהל המכון הביולוגי לשעבר כלכליסט
The Israeli company, Sent-Tech Medical, has replaced its Chief Technology Officer, Harel Rashtik, with former director of the Biological Institute, Prof. Shmuel Shapira. This move comes four months after it was revealed that Rashtik, who was trying to take the company public through a merger with Next Gen, is a released murderer. The company hopes that this change in management will help salvage the delayed merger. Rashtik will continue to work in the company as a scientific development worker.
Management Changes
סנט־טק מתעקשת למכור חלום שהיא נכשלת בהגשמתו כלכליסט
The article discusses the planned merger of Next Gen and Scent Tech, a company developing a breathalyzer for diagnosing COVID-19. The merger is currently delayed due to regulatory issues and questions about the effectiveness of Scent Techs technology. The article also mentions that Scent Tech has a gallery of famous role holders who will surely assist in raising capital. The companys valuation is estimated to be high for a company in the initial development stage. The article raises concerns about the companys technology and its effectiveness.
AcquisitionManagement Changes
From prison to the TASE: the convicted murderer seeking a $250 million valuation
Harel Hershtik, a convicted murderer, has been released from prison after 25 years and is now leading NextGen BioMed Ltd., a company he founded. The company is planning to merge with Scentech Medical, which Hershtik also founded. Hershtik, who completed two doctorates in prison, is developing a breathalyzer that can detect viruses and malignant diseases, with a focus on identifying the coronavirus. The shareholders of NextGen will vote on Hershtiks appointment as the companys CTO. The merger agreement between NextGen and Scentech did not materialize due to a dispute among Scentech shareholders. The largest investor in Scentech is Drew Morris. The compensation terms for investors assume that the merged company will reach a market value of at least NIS 800 million. Hershtik will receive options for 0.75% of the companys shares as CTO.
AcquisitionManagement Changes
לקראת המיזוג לנקסט גן: סנט טק חתמה על שת"פ עם המכון הביולוגי
Scent Tech Medical, a company developing a device for rapid diagnosis of COVID-19, has signed a cooperation agreement with the commercial arm of the Biological Research Institute in Israel. The two entities will collaborate on research to validate the biological markers identified by Scent Tech as relevant for identifying the coronavirus, as well as search for additional biological markers. The total budget for the project is 620,000 shekels, which will be fully funded by Scent Tech. If FDA approval for the product is received, Scent Tech will pay the Biological Institute $250,000.
PartnersAcquired-by
נקסט-ג'ן: סנט-טק רוכשת 100 מערכות VOX מחברה גרמנית
NextGen Biomed, in the process of merging with Sant-Tech Medical, has announced a partnership with a German company to supply 100 VOX diagnostic systems for early detection of COVID-19. The VOX system is currently undergoing testing and validation at the Sheba Medical Center. The contract with the German supplier is for 5 years, and NextGen Biomed is obligated to order at least 5 diagnostic systems through breath analysis. The company has achieved significant results in the analysis of breath samples from COVID-19 patients and healthy volunteers, demonstrating high sensitivity and specificity. The identified biomarkers serve as a scientific breakthrough and the basis for building a commercial system (VOX) for COVID-19, mutations, and immune status. NextGen Biomed is preparing to file patents for the identified biomarkers.
PartnersCustomers
https://www.jpost.com/health-science/israeli-company-develops-breathalyzer-covid-19-test-with-98-percent-accuracy-655657
Israeli breath test diagnostics company Scentech Medical has developed a newer, more efficient coronavirus test with 98% accuracy. The test, which takes just a few minutes to perform, uses a breathalyzer-like device to detect COVID-19 by analyzing gas compounds in the breath. While the test is still in its testing stages and has not yet received FDA approval, it has shown higher sensitivity and specificity than existing commercial tests. Scentech hopes to speed up the testing process to achieve a 30-second test. The company is in the process of merging with Next-Gen medical and has been in discussions with foreign governments for marketing the product abroad.
InvestmentAcquisition
NextGen announce Ground-breaking Clinical Trial: Rapid breath test for Covid-19 detection to evaluate the efficacy of the vaccines including the Pfizer-BioNTech's vaccine
NextGen Biomed Ltd. reports that Scentech-Medical has received approval for a new clinical trial to monitor antibody levels and type in subjects getting vaccinated for the coronavirus. The trial aims to demonstrate the efficacy of vaccines and the immune systems response. Scentech-Medical is also conducting a clinical trial for the detection of coronavirus positive subjects. The company believes its breath test technology can detect symptomatic and asymptomatic carriers. Scentech-Medical is working on completing its global analysis system for real-time disease monitoring and detection. The company focuses on developing technologies for early and rapid disease detection through breath analysis.
Acquisition
נקסט ג'ן: סנט טק תערוך ניסוי לבדיקת יעילות חיסוני הקורונה
Next Gen, which is in the process of merging with Scent-Tech Medical, has begun a world-first clinical study to examine the companys technologys ability to monitor antibody levels in the vaccinated population for the coronavirus. The clinical study is expected to last three months and will provide the company with technology capable of diagnosing the effectiveness of coronavirus vaccines. Scent-Tech Medical is also continuing a clinical trial to identify coronavirus patients in field conditions, at Asaf Harofe Hospital (Shamir).
Acquired-byExpand
נקסט ג'ן: סנט טק החלה בבדיקות וולידציה לקראת אישור FDA
Next Gen Biomed, a listed company, is in the process of merging with Sant-Tech Medical. Sant-Tech has begun a wide-scale validation process of Next Gen Biomeds technology for the rapid diagnosis of the SARS-CoV-2 virus. This validation process includes clinical trials with around 4,000 participants. Next Gen Biomed has already completed the preliminary mapping phase and will continue testing thousands of samples to further develop and refine the technology. The company aims to become a global standard for the detection of various viruses through breath analysis, including different types of cancer. The technology is expected to provide quick and accurate results within seconds.
InvestmentAcquisition
NextGen Biomed trial brings Covid-19 breath test nearer
NextGen Biomed Ltd., an Israeli company, saw its share price jump 35% after news that it is merging with Scentech, a company that has successfully identified Covid-19 biomarkers through gas compounds. Scentech has reported initial success in mapping the fingerprint of Covid-19 and plans to produce a breath test for the virus. NextGen and Scentech will conduct validation trials to comply with regulatory standards and seek marketing approval from the US Food and Drug Administration and Israels Ministry of Health. The companies hope to offer a reliable, cheaper, and more rapid alternative to existing tests. The merger and potential development of a breath test have had a positive impact on NextGen Biomeds growth.
InvestmentAcquisitionPublic Trading
נקסט ג'ן: סנט-טק מדווחת על התקדמות בפיתוח בדיקת קורונה מהירה
NextGen (Shimur) reports that Sant-Tech Ltd., which signed a binding merger agreement with the company, has successfully completed the clinical trial at the Meir Medical Center in Kfar Saba. The trial involved testing breath samples from over 36 hospitalized COVID-19 patients and 18 confirmed healthy individuals. The companys advanced analysis system will enable the identification of the genetic expression of the coronavirus in patients, providing the ability to detect COVID-19 through breath samples. The company plans to conduct additional clinical trials on symptomatic and asymptomatic patients to demonstrate the systems efficacy.
InvestmentExpand
Aiming for 10-second result, breathalyzer detector for COVID begins early tests
Israeli startup Scentech Medical is conducting tests on a breath test technology that aims to identify the genetic fingerprint of the coronavirus. The test, if successful, could yield results within 10 seconds and be non-invasive. Scentech Medical hopes that the test could be available within weeks and believes it could help open borders and allow the world to return to normal. The company was already developing the technology for cancer and infectious diseases before pivoting to COVID-19. The technology uses a mix of hardware and software to identify volatile chemical compounds in breath. The test is currently being trialed at the Meir Medical Center in Kfar Saba.
Customers
Israeli startup's breath test device to sniff out COVID-19 set to start trials
Israeli startup Scentech Medical is starting a trial of its breath analysis technology with the Meir Medical Center to detect the coronavirus. The technology, which uses a mix of software and hardware, aims to identify the virus through the analysis of breath biomarkers. The trial will initially involve 50-60 coronavirus patients and healthy individuals, and will later expand to include 100-200 ill and healthy soldiers in the Israeli army. The company hopes that the technology will help identify patients before symptoms appear, thus aiding in the prevention of the virus spread.
Customers
https://www.jpost.com/health-science/diagnosing-the-coronavirus-in-under-a-minute-with-israeli-tech-625123
Next-Gen and Scentech Medical have developed a new method using a breathing device that can potentially diagnose the coronavirus in under a minute. The method has been approved by the Institutional Review Board. Patients breathe into the device, which can distinguish between gas compounds in the breath associated with the virus. The device can be used anywhere and provides quick and simple diagnostic tests. Next-Gen and Scentech Medical collaborated with Meir Medical Center to conduct the experiment on coronavirus patients. The new method offers several benefits, including the ability to diagnose asymptomatic patients and reduce diagnosis time to minutes. It also has the potential to identify the genetic fingerprint of future pandemic-causing viruses. The technology is considered revolutionary in the diagnostic field.
CustomersPartners
